Inventiva S.A. (EPA:IVA)
France · Delayed Price · Currency is EUR 3.770
-0.030 (-0.79%)
Aug 3, 2026, 1:39 PM CET
Inventiva Revenue
In the year 2025, Inventiva had annual revenue of 7.93M EUR, down -46.17%. Inventiva had revenue of 2.32M in the half year ending December 31, 2025, a decrease of -86.00%.
Revenue
7.93M
Revenue Growth
-46.17%
P/S Ratio
132.80
Revenue / Employee
92.62K
Employees
77
Market Cap
897.86M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.93M | -6.80M | -46.17% |
| Dec 31, 2024 | 14.72M | -8.44M | -36.43% |
| Dec 31, 2023 | 23.16M | 4.35M | 23.12% |
| Dec 31, 2022 | 18.81M | 10.31M | 121.32% |
| Dec 31, 2021 | 8.50M | 3.24M | 61.52% |
| Dec 31, 2020 | 5.26M | -6.03M | -53.39% |
| Dec 31, 2019 | 11.29M | 3.91M | 53.02% |
| Dec 31, 2018 | 7.38M | -2.58M | -25.90% |
| Dec 31, 2017 | 9.96M | -4.39M | -30.61% |
| Dec 31, 2016 | 14.35M | 5.69M | 65.66% |
| Dec 31, 2015 | 8.66M | 2.36M | 37.55% |
| Dec 31, 2014 | 6.30M | 1.20M | 23.46% |
| Dec 31, 2013 | 5.10M | 5.06M | 10,977.18% |
| Dec 31, 2012 | 46.06K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 156.33M |
| Genfit | 70.85M |
| Cellectis | 65.14M |
| Nanobiotix | 32.59M |
| MedinCell | 24.28M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Sensorion | 5.81M |
Inventiva News
- 3 days ago - Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹ - GlobeNewsWire
- 4 days ago - Inventiva Announces Preliminary Financial Results for the First Half of 2026¹ - GlobeNewsWire
- 4 days ago - Inventiva Earnings release: Q2 2026 - Filings
- 17 days ago - Inventiva initiated with an Overweight at Cantor Fitzgerald - TheFly
- 24 days ago - Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants - GlobeNewsWire
- 4 weeks ago - Results of the Votes of the Combined Shareholders' General Meeting of June 30, 2026 - GlobeNewsWire
- 6 weeks ago - Claret Capital Partners participates in €130m financing for Inventiva - GlobeNewsWire
- 6 weeks ago - Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development - GlobeNewsWire